Stay in the know. Connect with your peers and hear the latest irritable bowel syndrome with diarrhea (IBS-D) research at upcoming live and virtual events.

Please note that the status of scientific meetings may change at any time. Please visit the organization or meeting website for the latest updates regarding occurrence and scheduling.

American Academy of Physician Assistants (AAPA) Conference

American Academy of Physician Assistants (AAPA) Conference

Location: Nashville, TN Date: May 20–24, 2023

Shape your future with networking events and leadership training. Advance your patient care with new clinical skills. Challenge yourself to make new connections and do your part to bring down practice barriers for PAs.

Event details & registration

Digestive Disease Week® (DDW)

Digestive Disease Week® (DDW)

Location: Chicago, IL + Virtual Date: May 6–9, 2023

Attend the world’s largest gathering of physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Event details & registration

Society of Gastroenterology Nurses and Associates (SGNA) Annual Course

Society of Gastroenterology Nurses and Associates (SGNA) Annual Course

Location: Phoenix, AZ Date: May 7–9, 2023

Receive the tools and knowledge base you need to bring value to your workplace and your patients every day.

Event details & registration

American Association of Nurse Practitioners (AANP) National Conference

American Association of Nurse Practitioners (AANP) National Conference

Location: New Orleans, LA Date: June 20–25, 2023

Find opportunities for collegial networking with thousands of NPs at the largest annual event providing educational content for NPs of all specialties.

Event details & registration

Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) Conference

Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) Conference

Location: National Harbor, MD Date: September 7–9, 2023

Attend the only conference specifically designed by Advanced Practice Providers (APPs) for the purpose of meeting the educational needs of clinicians who specialize in the management of patients with gastroenterological disorders and chronic liver disease.

Event details & registration

American College of Gastroenterology (ACG) Annual Scientific Meeting

American College of Gastroenterology (ACG) Annual Scientific Meeting

Location: Vancouver, BC, Canada Date: October 20–25, 2023

Join gastroenterology physicians from the United States and around the world for the latest clinical information on timely topics in gastroenterology and hepatology.

Event details & registration

World Congress of Gastroenterology (WCOG)

World Congress of Gastroenterology (WCOG)

Location: Seoul, Korea Date: November 15–18, 2023

The World Congress of Gastroenterology 2023 will be held in partnership with the Korean Society of Gastroenterology.

Event details & registration

GI and Liver Association of the Americas (GALA) Annual and Regional Conferences

GI and Liver Association of the Americas (GALA) Annual and Regional Conferences

GALA unites health care providers across the Americas who are treating patients with chronic liver and gastrointestinal diseases. These conferences aim to provide extensive information on new treatment options, evolving data on existing treatment and diagnostic modalities, and critical information on improving patient outcomes.

Event details & registration
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN were:
    • HE (≥10%): Peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%)
    • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

SEE MORE

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.